Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06524375
Title A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period (BRAVE)
Acronym BRAVE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Rocky Mountain Cancer Centers (Aurora) - USOR RECRUITING Aurora Colorado 80012 United States Details
Fort Wayne Medical Oncology and Hematology, Inc RECRUITING Fort Wayne Indiana 46804 United States Details
Nebraska Cancer Specialists St Francis - Grand Island RECRUITING Grand Island Nebraska 68803 United States Details
Nebraska Cancer Specialists RECRUITING Omaha Nebraska 68114 United States Details
Astera Cancer Care East Brunswick RECRUITING East Brunswick New Jersey 08816 United States Details
San Juan Oncology Associates, PC RECRUITING Farmington New Mexico 87401 United States Details
Oncology Hematology Care Inc - Cincinnati - USOR RECRUITING Cincinnati Ohio 45226 United States Details
Oncology Associates of Oregon, P.C. RECRUITING Eugene Oregon 97401 United States Details
Texas Oncology- Northeast Texas RECRUITING Tyler Texas 75702 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field